We established two Epstein -Barr virus (EBV)-infected NKL sublines, which acquired stress resistant phenotype against DNA damage and starvation compared with EBV-negative NKL. EBV-rendered doxorubicin resistance at least partially through NF-kB activation and the resultant sustenance of antiapoptotic proteins including Bcl-X L and FLIP L/S .
MATERIALS AND METHODS

Establishment of EBV-infected NKL sublines
Cell-culture condition and infection procedure were described earlier (Isobe et al, 2004) . We used EBV-negative NK-cell leukaemia cell line, NKL as an EBV target cell (Robertson et al, 1996) . NKL was maintained in Iscove's modified Dulbecco's medium (Invitrogen, Carlsbad, CA, USA) containing 100 U ml À1 human interleukin (IL)-2 (a gift from Shionogi, Osaka, Japan). We previously confirmed that this cell line had no mutations in exon 5-to-8 of TP53 gene (Sakajiri et al, 2001) . Akata (EBV-positive) and BJAB (EBV-negative) were used as an EBV-producing cell and an EBV target control, respectively. Akata is infected with recombinant EBV strain containing neomycin-resistant gene (Yoshiyama et al, 1995) . After selection with medium containing 700 mg ml À1 of G418 (Invitrogen), EBV-infected clones were maintained for more than four years using G418-free medium. BJAB was obtained from Fujisaki Cell Center, Hayashibara biochemical laboratories Inc. (Okayama, Japan). 4-hydroxycyclophosphamide (HC) (a gift from Shionogi), doxorubicin (DXR), vincristine (VCR) (Sigma-Aldrich), and I-kB kinase inhibitor BMS-345541 (Merck KGaA, Darmstadt, Germany). We assessed the cell viability using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Promega). The viability was calculated as percent absorbance of formazan products, that is, (OD570DXR-treated/OD570control) Â 100%. We also evaluated the cell death process by FITC-conjugated annexin V-binding and 7-amino actinomycin D (AAD)-rejection assays (Beckman Coulter, Fullerton, CA, USA). DNA nick ends in apoptotic cells were labelled with fluorescein isothiocyanate (FITC)-conjugated dUTP using Mebstain Apoptosis Kit (Beckman Coulter) and analysed by flow cytometry.
Nuclear factor-jB activity assay DNA binding activity of nuclear factor (NF)-kB was evaluated using an enzyme-linked immunosorbent assay method. Nuclear extract (10 mg) was isolated from DXR-treated and untreated cells and assayed using NF-kB p65 Transcription Factor assay Kit (Chemicon). Relative absorbance was calculated as follows: OD450/OD650 -OD450control/OD650control. NKL   TL1   TL2   100  90  80  70  60  50  40  30  20  10  0   100  90  80  70  60  50  40  30  20  10  0   100  90  80  70  60  50  40  30  20  10  0   100  90  80  70  60  50  40  30  20  10  0   100  90  80  70  60  50  40  30  20  10  0   100  90  80  70  60  50  40  30  20  10  0   100  90  80  70  60  50  40  30  20  10  0   100  90  80  70  60  50  40  30 
RESULTS
Establishment of EBV-carrying NKL sublines
We initially obtained three G418-resistant NKL subclones containing monoclonal EBV genome ( Figure 1A ). During the 4 years of incubation, clone 2 stopped proliferation, and we finally established two EBV-infected sublines named TL1 and TL2. Western blot analysis showed expression of EBNA1 in all EBV-infected subclones ( Figure 1B ). EBNA2 and lytic marker proteins, ZEBRA and EA-D were absent in these clones. In addition, LMP1 was detected in TL1 and TL2 but not in clone 2. LMP1 in TL1 and TL2 showed smaller sizes than that in EBV-infected BJAB ( Figure 1B ). These truncated forms resemble lytic LMP1 detected in TPA-treated Akata ( Figure 1B) . Because lytic marker proteins were absent in both sublines, detection of the truncated forms may represent rapid turnover of LMP1 in TL1 and TL2.
EBV infection of NKL showed no growth advantage but rendered the infected cells resistant to doxorubicininduced apoptosis NKL and EBV-infected TL1 and TL2 showed no difference in cell growth at a steady state ( Figure 1C ). After treatment with 150 nM of DXR, both sublines remained more viable than NKL, that is, although approximately 60% of NKL cells became positive for trypan-blue dye exclusion assay after 48 h, less than 14% of TL1 and TL2 cells were dead ( Figure 1D) . Indeed, about half of NKL cells underwent apoptosis after the DXR treatment ( Figure 1E) . We also evaluated possible difference of drug sensitivity among NKL, TL1 and TL2 using 4-HC, DXR, VCR, and I-kB kinase inhibitor BMS-345541. After 48 h of treatment, MTT assay showed that TL1 and TL2 were more resistant to DXR than NKL ( Figure 1F ). Although NKL itself was rather resistant to VCR compared with BJAB, the sublines were a little more refractory to the agent. The effect of 4-HC or BMS-345541 on cell viability was almost equal between NKL and its sublines. Flow cytometric terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling assay showed that treatment with 150 nM of DXR or serum depletion (10% to 0.1%) for 48 h induced apoptosis in about half of NKL cells but in only few TL1 and TL2 cells ( Figure 1G ). Annexin V-binding and 7-AAD-rejection assays confirmed the loss of susceptibility to DXR and serum depletion in TL-1 and TL-2 ( Figure 1H ). These results showed that EBV rendered the infected NKL cells resistant to various cell stresses like DNA damage and starvation. Figure 2 Continued.
EBV infection of NKL cells Y Isobe et al
We next evaluated possible alterations of antiapoptotic proteins after EBV infection of NKL cells. Western blot analysis showed essentially the same levels of Bcl-2, Bcl-X L , Mcl-1, Bax, p53 and FLIP L/S among NKL, TL1 and TL2 (Figure 2A) . Expression of MDR1-encoded P-gp was absent in all these lines, which confirmed that the resistance to DXR should be unrelated to drug pumping ( Figure 2B ). Although no apparent difference was detected at the steady state, treatment with 150 nM of DXR for 24 h reduced expression levels of Bcl-2, Bcl-X L , and FLIP L/S specifically in NKL ( Figure 2C ). The amounts of these proteins were constant or rather increased in TL1 and TL2 after the same treatment. Protein levels of Mcl-1 and Bax were unchanged in all three lines ( Figure 2C ). Increased levels of p53 phosphorylation at serine-15 after DXR treatment indicated preservation of normal p53 activity in all three lines ( Figure 2C ). Because nuclear factor (NF)-kB is reported to affect expression levels of Bcl-X L and FLIP L/S (Karin, 2006) , we examined possible involvement of NF-kB in the EBV-mediated resistance to DXR. In spite of a transient increase at 12 h, target sequences-binding activity of NF-kB p65 clearly regressed after 24 h of DXR treatment in NKL ( Figure 2D ). In contrast, although the basal activities in TL1 and TL2 were rather suppressed, they increased approximately five times as high as their basal levels after 12 h of DXR treatment, and were further boosted at 24 h ( Figure 2D ). However, NF-kB inhibitor BMS-345541 almost completely suppressed DXR-induced NF-kB activation in all three lines. In the presence of this inhibitor, treatment with DXR clearly decreased expression levels of Bcl-X L and FLIP L/S and induced massive apoptosis even in TL1 and TL2 ( Figure 2E and F). It should be noted that BMS-345541 rather decreased the apoptotic cell percentage from approximately 60% to around 35% in DXRtreated NKL. These experiments were repeated at least three times with essentially the same results.
DISCUSSION
In this study, we established TL1 and TL2, which contain monoclonal EBV genome and showed type II latency. Their manner of infection corresponds to the clinical setting of NK-cell malignancies (Xu et al, 2001) . The intense signals in Southern blot analysis suggested that TL1 and TL2 should contain greater copy number of EBV genome than clone 2 ( Figure 1A ). Relatively high copy number of EBV may contribute to successful maintenance of TL1 and TL2 over 4 years. We previously detected truncated forms of LMP1 at a later phase of latent infection (Isobe et al, 2004) . Although full-length LMP1 induces NF-kB activation, its truncated form is reported to inhibit this effect (Erickson and Martin, 2000) . The canonical function of LMP1 seems to be limited and might not fully contribute to establish the latent infection in both NKL sublines. These truncated forms might explain the relatively low basal NF-kB activity in TL1 and TL2 compared with NKL. Of course, latent EBV infection may exert a supportive role for the NF-kB pathway and might lessen its activity without altering basal cell growth activity in both sublines.
At a steady state, TL1 and TL2 had no growth advantage and showed essentially the same expression levels of several antiapoptotic proteins as NKL. However, these EBV-infected sublines were apparently more resistant to DXR and serum depletion than NKL. The results indicate that EBV infection conferred resistance to various cell stresses like DNA damage and starvation in NKL. Expression levels of Bcl-2, Bcl-X L and FLIP L/S decreased in NKL but not in two sublines after DXR treatment. In the presence of NF-kB inhibitor BMS-345541, both NKL and the EBV-infected sublines were almost equally sensitive to DXR and failed to maintain the expression levels of Bcl-X L and FLIP L/S after DXR treatment. The results are completely in line with the previous report that constitutively activated NF-kB has shown to maintain high expression levels of Bcl-X L and FLIP L/S and confer resistance to some anticancer drugs (Wang et al, 1999; Karin, 2006) . EBVassociated gene products like EBNA1 and LMP1 were reported to modify the ubiquitin -proteasome activity and affect proteolysis of various cellular proteins including NF-kB (Masucci, 2004) . In addition, EBERs appear to be involved in modulation of cellular response and were reported to activate NF-kB-signalling pathway (Nambo and Takada, 2002; Samanta et al, 2006) . These observations strongly argue that the presence of EBV must render NKL more resistant to lethal stress like DNA damage at least partially through the NF-kB pathway.
During a series of experiments aimed to show the contribution of NF-kB activity in stress resistance of TL1 and TL2, we found that BMS-345541 reproducibly attenuated DXR-induced apoptosis in NKL cells. Atypical activators of NF-kB including DXR have been shown to convert p65 from a transcriptional activator into a transcriptional repressor of antiapoptotic genes including Bcl-X L and FLIP L/S (Campbell et al, 2004; Dutta et al, 2006) . We believe that DXR may induce apoptosis in NKL at least partially through this atypical activation of NF-kB. Prolonged activation of NF-kB during DXR treatment maintained high expression levels of Bcl-X L and FLIP L/S in the EBV-infected sublines. Therefore, we suppose that in the presence of some EBV-associated gene products, even DXR treatment may preferentially elicit classical NF-kB activity with an antiapoptotic feature rather than inducing the proapoptotic situation and thus render the cell resistant to apoptosis. Abrogation of both positive and negative impacts of NF-kB on apoptosis by BMS-345541 should bring about essentially the same behaviour of NKL, TL1 and TL2 toward the DXR treatment.
In conclusion, we report here in vitro establishment of two EBV-infected NKL sublines, TL1 and TL2. Although the infected sublines had no growth advantage compared with NKL, they showed a resistant phenotype to stress-induced apoptosis at least partially through the NF-kB activation and the resultant sustenance of Bcl-X L and FLIP L/S . We believe that this model suggests the contribution of EBV in NK-cell tumorigenesis.
